MAP1LC3A and hepatocellular carcinoma: For HCC recurrence, compared to patients (n = 289) with low Axl and high LC3 expression in tumors, patients (n = 29) with high Axl and low LC3 expression had the highest risk of HCC recurrence (HR: 6.53, 95% CI: 4.11‐10.4, P < 0.001), followed by those (n = 201) with high Axl and high LC3 expression (HR: 4.04, 95% CI: 3.05‐5.35, P < 0.001) and those (n = 16) with low Axl and low LC3 expression (HR: 2.99, 95% CI: 1.60‐5.59, P = 0.001).